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journals were compared using descriptive and compara-
tive chi-squared statistics.
RESULTS: 4,036 advertisements were identiﬁed from all
issues in three General and three MC journals with 194
unique advertisements evaluated for potential outcomes
messages. General and MC journals had QoL messages
included in 36.0% and 41.7% of advertisements (p <
0.005) and pharmacoeconomic messages in 7.3% and
9.0% of advertisements (p = 0.08), respectively. MC jour-
nals had more advertisements detailing pharmaceutical
expenditure savings (p = 0.01) and listing speciﬁc costs 
(p = 0.001). Trends for increased implicit QoL (p = 0.07)
and QoL references (p = 0.08) in advertisements were
found in MC journals.
CONCLUSIONS: Leading journals contain large
numbers of QoL advertisements, with MC having signif-
icantly more than General journals. MC journals are 
also more speciﬁc as to the details of the cost data,
however very few advertisements contain these messages.
Increased detail in both QoL and pharmacoeconomic
advertisements will help improve communication of this
timely data.
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OBJECTIVE: To perform a systematic review of the 
literature pertaining to the efﬁcacy of amlodipine
monotherapy in reducing systolic blood pressure (SBP) in
a variety of patient subgroups. The sixth report of the
Joint National Committee on Prevention, Detection,
Evaluation, and Treatment of High Blood Pressure (JNC
VI) recommends diuretics or long-acting dihydropyridine
calcium channel blockers (CCBs) for the treatment of 
isolated systolic hypertension (ISH). Amlodipine is the
most commonly prescribed CCB worldwide; therefore, a
systematic review was performed to capture the impact
of amlodipine monotherapy on SBP. 
METHODS: Following a protocol that had been devel-
oped a priori, published literature in ﬁve languages was
searched from 1980 to 2001, using three electronic data-
bases and manual bibliography checks of recent review
articles and all accepted studies. Randomized controlled
trials with at least 10 patients, one treatment arm of
amlodipine monotherapy, minimum treatment duration
of 8 weeks, reporting baseline and endpoint BP, and pres-
ence of baseline hypertension (deﬁned as SBP ≥140mm
Hg, diastolic blood pressure (DBP) ≥90mmHg, or both)
were accepted for this systematic review.
RESULTS: A total of 696 citations were reviewed, of
which 85 met all inclusion criteria. Comparable treatment
arms were pooled, and weighted means of efﬁcacy results
were calculated. In the amlodipine monotherapy arms,
representing over 5,000 patients treated with the drug,
amlodipine reduced SBP by an average of 17.5mmHg
from baseline (an estimated 13.3mmHg more than
placebo). The effect of amlodipine in reducing SBP was
even more marked in elderly patients (24.1mmHg mean
reduction), black patients (23.9mmHg mean reduction),
and patients with ISH (25.9mmHg mean reduction),
although the number of studies investigating these special
populations was small. 
CONCLUSION: Amlodipine is effective for reducing
SBP. Long-term trials are needed to correlate SBP reduc-
tion with clinical outcomes.
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OBJECTIVES: To quantify the incidence of major
adverse events (AE) occurring in hospital or within 30
days after surgery in patients undergoing coronary artery
bypass grafting (CABG), and identify risk factors for
these AEs. 
METHODS: A systematic review and analysis of studies
published in English since 1990. Studies of isolated 
standard CABG reporting post-operative incidence of
myocardial infarction (MI), stroke, GI bleeding, renal
failure, or death in hospital or within 30 days, were 
eligible. The incidence of these events was calculated
overall, and for selected patient groups deﬁned by: all
elective CABG vs. mixed (elective and urgent/emergency
CABG); mean ejection fraction (EF) <50% vs. >50%;
mean age <60 years vs. >60 years; primary CABG only
vs. some patients with reoperations; RCTs vs. cohort
studies; single center vs. multicenter studies. Odds ratios
of selected AEs were computed according to group risk
factors.
RESULTS: 176 studies (205,717 patients) met all inclu-
sion criteria. The average incidence of major AEs occur-
ring in-hospital was: death -1.7% (range 0%–6.6%),
non-fatal MI—2.4% (range 0%–13.9%), non-fatal
stroke—1.3% (range 0%–3.2%), GI bleeding—1.5%
(range 0.7%–2.7%), and renal failure requiring dialysis—
0.8% (range 0%–6.2%). Thirty-day mortality was 2.1%
(range 0%–7.7%). Subset analyses revealed interesting
differences in overall mortality and MI incidence by
groups with all elective vs. mixed CABG, by study design,
mean age, primary CABG vs. some patients with re-
operation, and by number of study sites. Meta-analyses
of odds ratios suggest that old age (>70 years); female
gender; low EF; history of stroke, MI, or heart surgery;
